Plain-English translation of NCT07283367 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called HS-20110 to see if it works better when combined with standard colorectal cancer treatments. Researchers want to understand how safe the medication is, how your body processes it, and whether it helps slow or stop cancer growth. The study will first test different dose levels to find the safest and most effective amount, then test that dose in a larger group of patients.
Advanced colorectal cancer is difficult to treat, and current treatments don't work well enough for all patients. This trial exists to see if adding this new medication to existing treatments can improve outcomes and give patients more options.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication (HS-20110) by infusion along with standard cancer drugs like bevacizumab, chemotherapy, or both, given every 2–3 weeks depending on which treatment group you're in. You'll have regular visits to the hospital or clinic for treatment, blood tests, and imaging scans to check how you're responding. The study will monitor you closely for side effects and track how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China